

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. **(Previously presented)** A method for treating or preventing cancer comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof, wherein said X-nitro compound comprises (i) a nitrocarbon, (ii) a nitroamine or (iii) a nitrocarbon and a nitroamine.
2. **(Previously presented)** The method of Claim 1, further comprising irradiating the patient.
3. **(Withdrawn)** A pharmaceutical composition comprising a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof and a pharmaceutically acceptable diluent, excipient or adjuvant.
4. **(Previously presented)** A method for treating or preventing cancer comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a pharmaceutical composition comprising a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof and a pharmaceutically acceptable diluent, excipient or adjuvant, wherein said X-nitro compound comprises (i) a nitrocarbon, (ii) a nitroamine or (iii) a nitrocarbon and a nitroamine.
5. **(Original)** The method of Claim 4, further comprising irradiating the portion of the patient which contains the cancer.
6. **(Original)** The method of any one of Claims 1, 2, 4 or 5 further comprising administering to the patient a therapeutically effective amount of another anti-cancer agent or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof or a pharmaceutical composition comprising the other anti-cancer agent or a pharmaceutically

acceptable salt, hydrate, N-oxide or solvate thereof and a pharmaceutically acceptable diluent, excipient or adjuvant.

7. **(Original)** The method of any one of Claims 1, 2, 4 or 5, wherein the cancer is breast cancer, renal cancer, brain cancer, colon cancer, colorectal cancer, prostate cancer or lung cancer.

8. **(Previously presented)** The method of any one of Claims 1, 2, 4 or 5, wherein the X-nitro compound comprises two nitro groups.

9. **(Previously presented)** The method of any one of Claims 1, 2, 4 or 5, wherein the X-nitro compound comprises three or more nitro groups.

10. **(Original)** The method of any one of Claims 1, 2, 4 or 5, wherein the X-nitro compound is 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.0^{5,9}.0^{3,11}]dodecane, 1,3,5-trinitro-1,3,5-triazacyclohexane, 1,3,5,7-tetranitro-1,3,5,7 tetraazacyclooctane, 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo[5.5.0.0^{5,9}.0^{3,11}]dodecane, 3-nitro-1,2,4-triazol-5-one, nitroguanidine, 1,3,3 trinitroazetidide, ammonium dinitride, 1,1,-diamino-2,2-dinitroethane, tetranitrocarbazole or tetranitrodibenzo-1,3a,4,6a tetraazapentalene.

11. **(Withdrawn)** The method of any one of Claims 1, 2, 4 or 5, wherein the X-nitro compound is 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.0^{5,9}.0^{3,11}]dodecane, 1,3,5-trinitro-1,3,5-triazacyclohexane or 1,3,5,7-tetranitro-1,3,5,7 tetraazacyclooctane.

12. **(Original)** The method of Claim 2, wherein a portion of the patient is irradiated.

13. **(Original)** The method of Claim 12, wherein the irradiated portion is the portion which is cancerous.

14. **(Original)** The method of Claim 2, wherein the patient is irradiated with photons, electrons or gamma rays.

15. **(Previously presented)** A method for treating hypoxic tumor cells comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof and a pharmaceutically acceptable diluent, excipient or adjuvant, wherein said X-nitro compound comprises (i) a nitrocarbon, (ii) a nitroamine or (iii) a nitrocarbon and a nitroamine.

16. **(Previously presented)** A method for treating hypoxic tumor cells comprising administering to a patient in need of such treatment a therapeutically effective amount of a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof, wherein said X-nitro compound comprises (i) a nitrocarbon, (ii) a nitroamine or (iii) a nitrocarbon and a nitroamine.

17. **(Previously presented)** A method for treating or preventing solid tumors comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a pharmaceutical composition comprising a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof and a pharmaceutically acceptable diluent, excipient or adjuvant, wherein said X-nitro compound comprises (i) a nitrocarbon, (ii) a nitroamine or (iii) a nitrocarbon and a nitroamine.

18. **(Previously presented)** A method for treating or preventing solid tumors comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof, wherein said X-nitro compound comprises (i) a nitrocarbon, (ii) a nitroamine or (iii) a nitrocarbon and a nitroamine.

19. **(Original)** The method of any one of Claims 15-18 further comprising irradiating the patient.

20. **(Withdrawn)** A method for treating or preventing inflammation comprising administering to a patient in need of such treatment or prevention a therapeutically

effective amount of a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof.

21. **(Withdrawn)** The method of Claim 20, further comprising irradiating the patient.

22. **(Withdrawn)** A method for treating or preventing inflammation comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of the pharmaceutical composition of Claim 3.

23. **(Withdrawn)** The method of Claim 22, further comprising irradiating the patient.

24. **(Withdrawn)** A method for treating or preventing autoimmune disease comprising administering a patient in need of such treatment or prevention a therapeutically effective amount of a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxide or solvate thereof.

25. **(Withdrawn)** The method of Claim 24, further comprising irradiating the patient.

26. **(Withdrawn)** A method for treating or preventing inflammation comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of the pharmaceutical composition of Claim 3.

27. **(Withdrawn)** The method of Claim 26, further comprising irradiating the patient.

28. **(Withdrawn)** A method for treating or preventing cardiovascular disease comprising administering to a patient in need of such treatment or prevention of a therapeutically effective amount of a X-nitro compound or a pharmaceutically acceptable salt, hydrate, N-oxides or solvate thereof.

29. **(Withdrawn)** The method of Claim 28, further comprising irradiating the patient.

30. **(Withdrawn)** A method for treating or preventing cardiovascular disease comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of the pharmaceutical composition of Claim 3.

31. **(Withdrawn)** The method of Claim 30, further comprising irradiating the patient.
32. **(New)** The method of Claim 1, 4, 15, 16, 17 or 18 wherein said X-nitro compound has an enthalpy of formation between about 5 kcal/mole and about 150 kcal/mole.
33. **(New)** The method of Claim 1, 4, 15, 16, 17 or 18 wherein said X-nitro compound has an enthalpy of formation between about 10 kcal/mole and about 110 kcal/mole.